Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo
暂无分享,去创建一个
M. Dewhirst | O. Mawlawi | J. D. de Groot | D. Piwnica-Worms | J. Marszalek | M. D. Di Francesco | S. Gammon | F. Wong | Y. V. Vashisht Gopal | J. Ackroyd | Federica Pisaneschi | F. Muller | Yi Rao | Yuting Sun | M. Davies | Madhavi Bandi | Melinda G. Smith | M. Di Francesco | Florian Muller | Yuting Sun
[1] M. Protopopova,et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability , 2018, Nature Medicine.
[2] V. Bettinardi,et al. 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry. , 2018, Current radiopharmaceuticals.
[3] Jamey D. Young,et al. Lactate Metabolism in Human Lung Tumors , 2017, Cell.
[4] S. Indraccolo,et al. Linking metabolic reprogramming to therapy resistance in cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.
[5] S. Kreis,et al. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells , 2017, Molecular Cancer.
[6] S. Valable,et al. In Vivo Relationship Between Hypoxia and Angiogenesis in Human Glioblastoma: A Multimodal Imaging Study , 2017, The Journal of Nuclear Medicine.
[7] Wei Zhang,et al. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit , 2017, Oncotarget.
[8] M. Bernaudin,et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[9] J. Locasale,et al. Glutamine Metabolism in Cancer: Understanding the Heterogeneity. , 2017, Trends in cancer.
[10] Anne Bol,et al. Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy , 2017, Acta oncologica.
[11] G. Semenza. Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype , 2017, The EMBO journal.
[12] Q. Fu,et al. Preclinical pharmacokinetics and toxic kinetics study of 2, 4-dinitrophenol (DNP) , 2016 .
[13] K. Morten,et al. The Warburg effect: 80 years on , 2016, Biochemical Society transactions.
[14] Wei Zhang,et al. Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells* , 2016, The Journal of Biological Chemistry.
[15] A. V. van Kuilenburg,et al. Genotypes Affecting the Pharmacokinetics of Anticancer Drugs , 2016, Clinical Pharmacokinetics.
[16] R. DePinho,et al. SF2312 is a natural phosphonate inhibitor of Enolase , 2016, Nature chemical biology.
[17] C. Heeschen,et al. Hallmarks of cancer stem cell metabolism , 2016, British Journal of Cancer.
[18] Navdeep S. Chandel,et al. Fundamentals of cancer metabolism , 2016, Science Advances.
[19] D. Jaffray,et al. Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake , 2016, The Journal of Nuclear Medicine.
[20] B. Faubert,et al. Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.
[21] Andrea Glasauer,et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth , 2015, Cancer & metabolism.
[22] C. Heeschen,et al. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. , 2015, Cell metabolism.
[23] R. Steenbakkers,et al. Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] D. Sabatini,et al. An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis , 2015, Cell.
[25] A. Maity,et al. Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand , 2015, Clinical Cancer Research.
[26] J. Dick,et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. , 2015, Blood.
[27] P. Lambin,et al. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[28] A. Lane,et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. , 2015, The Journal of clinical investigation.
[29] Kakajan Komurov,et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. , 2014, Cancer research.
[30] S. Gambhir,et al. 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243 , 2014, Clinical Cancer Research.
[31] Robert J. Gillies,et al. Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302 , 2014, PloS one.
[32] M. Wuest,et al. Detecting functional changes with [18F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy , 2014, EJNMMI Research.
[33] Alexander G. Fletcher,et al. Oxygen consumption dynamics in steady-state tumour models , 2014, Royal Society Open Science.
[34] John M. Asara,et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.
[35] I. Hanamura,et al. Importance of Glutamine Metabolism in Leukemia Cells by Energy Production Through TCA Cycle and by Redox Homeostasis , 2014, Cancer investigation.
[36] V. Grégoire,et al. A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[37] Timothy W. Secomb,et al. Quantitative Mapping of Hemodynamics in the Lung, Brain, and Dorsal Window Chamber‐Grown Tumors Using a Novel, Automated Algorithm , 2013, Microcirculation.
[38] M. Dewhirst,et al. Catabolism of Exogenous Lactate Reveals It as a Legitimate Metabolic Substrate in Breast Cancer , 2013, PloS one.
[39] Michael R. Green,et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. , 2012, Cancer cell.
[40] Marit Holden,et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. , 2012, Cancer research.
[41] Anne Bol,et al. Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[42] John L. Humm,et al. Image-Guided Po2 Probe Measurements Correlated with Parametric Images Derived from 18F-Fluoromisonidazole Small-Animal PET Data in Rats , 2012, The Journal of Nuclear Medicine.
[43] Steen Jakobsen,et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[44] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[45] K. Houkin,et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[46] Jan J Wilkens,et al. Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications , 2011, Radiation oncology.
[47] Xiao-Hong Zhu,et al. In vivo oxygen-17 NMR for imaging brain oxygen metabolism at high field. , 2011, Progress in nuclear magnetic resonance spectroscopy.
[48] C. Dang,et al. Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.
[49] Bradford D Henderson,et al. Highlighting the Versatility of the Tracerlab Synthesis Modules. Part 1: Fully Automated Production of [F]Labelled Radiopharmaceuticals using a Tracerlab FX(FN). , 2011, Journal of labelled compounds & radiopharmaceuticals.
[50] Chi V. Dang,et al. Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.
[51] Richard Pötter,et al. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer , 2010, Acta oncologica.
[52] M. Roth,et al. Inhibition of Iron Uptake Is Responsible for Differential Sensitivity to V-ATPase Inhibitors in Several Cancer Cell Lines , 2010, PloS one.
[53] Jun Xu,et al. Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization , 2010, The Journal of Biological Chemistry.
[54] E. Graves,et al. Pharmacologically Increased Tumor Hypoxia Can Be Measured by 18F-Fluoroazomycin Arabinoside Positron Emission Tomography and Enhances Tumor Response to Hypoxic Cytotoxin PR-104 , 2009, Clinical Cancer Research.
[55] Terence A. Riauka,et al. Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA) , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[56] Jayne E. Telford,et al. Complex I Is Rate-limiting for Oxygen Consumption in the Nerve Terminal* , 2009, Journal of Biological Chemistry.
[57] Julien Verrax,et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.
[58] Kenneth A Krohn,et al. Molecular Imaging of Hypoxia , 2008, Journal of Nuclear Medicine.
[59] P. Workman,et al. Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. , 2007, Biomarkers in medicine.
[60] D. Hedley,et al. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX , 2007, Laboratory Investigation.
[61] N. Denko,et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.
[62] C. Solbach,et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[63] N. Denko,et al. Cellular reaction to hypoxia: sensing and responding to an adverse environment. , 2005, Mutation research.
[64] M. Holness,et al. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. , 2003, Biochemical Society transactions.
[65] H. Leong,et al. Glycolysis and pyruvate oxidation in cardiac hypertrophy--why so unbalanced? , 2003, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[66] P. Price,et al. PET for in vivo pharmacokinetic and pharmacodynamic measurements. , 2002, European journal of cancer.
[67] G. Semenza,et al. HIF-1, O2, and the 3 PHDs How Animal Cells Signal Hypoxia to the Nucleus , 2001, Cell.
[68] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[69] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[70] D. Voehringer,et al. Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[71] P. Vaupel,et al. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. , 2000, International journal of oncology.
[72] J P Logue,et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[73] A Brahme,et al. Development of Radiation Therapy Optimization , 2000, Acta oncologica.
[74] M. Dewhirst,et al. Microvascular studies on the origins of perfusion-limited hypoxia. , 1996, The British journal of cancer. Supplement.
[75] G L Rosner,et al. Arteriolar oxygenation in tumour and subcutaneous arterioles: effects of inspired air oxygen content. , 1996, The British journal of cancer. Supplement.
[76] M. Dewhirst,et al. Tumor oxygenation: a matter of supply and demand. , 1996, Anticancer research.
[77] O. J. Dunn. Multiple Comparisons among Means , 1961 .
[78] W. Scholz. The Contribution of Patho‐Anatomical Research to the Problem of Epilepsy , 1959 .
[79] D. Binns,et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[80] Morand Piert,et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[81] C. Koch,et al. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. , 2002, Methods in enzymology.
[82] J F Gross,et al. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. , 1995, Acta oncologica.
[83] John F. Nunn,et al. Respiratory Physiology—the essentials , 1975 .
[84] H. Krebs. The Pasteur effect and the relations between respiration and fermentation. , 1972, Essays in biochemistry.